Best Practice & Research Clinical Haematology最新文献_第10页

Acute GVHD: New approaches to clinical trial monitoring 急性GVHD:临床试验监测的新方法

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2022-12-01 DOI: 10.1016/j.beha.2022.101400

Nikolaos Spyrou, John E. Levine, James L.M. Ferrara

引用次数: 2

When will chemotherapy be replaced in upfront induction therapy for adult acute lymphoblastic leukemia (ALL)? 成人急性淋巴细胞白血病(ALL)的前期诱导治疗何时可以替代化疗?

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2022-12-01 DOI: 10.1016/j.beha.2022.101404

Anjali Advani

引用次数: 0

What are the long-term complications of pediatric ALL treatments and how can they be mitigated? Perspectives on long-term consequences of curative treatment in childhood ALL 儿科ALL治疗的长期并发症有哪些?如何减轻这些并发症?儿童ALL治疗的长期后果的观点

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2022-12-01 DOI: 10.1016/j.beha.2022.101403

Lia Gore

引用次数: 0

How can we design a better care model to address the acute distress of an acute leukemia diagnosis? Care models to address the acute distress of an acute leukemia diagnosis 我们如何设计一个更好的护理模式来解决急性白血病诊断的急性痛苦?护理模式，以解决急性白血病诊断的急性痛苦

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2022-12-01 DOI: 10.1016/j.beha.2022.101409

Areej El-Jawahri

引用次数: 0

How can we intervene to mitigate post-transplantation relapse in AML? Strategies to mitigate post-transplantation relapse in AML 我们如何干预以减轻AML移植后复发?减轻AML移植后复发的策略

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2022-12-01 DOI: 10.1016/j.beha.2022.101411

Jonathan A. Gutman

引用次数: 1

How can we incorporate molecular data into the IPSS? 我们如何将分子数据整合到IPSS中?

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2022-12-01 DOI: 10.1016/j.beha.2022.101410

Rafael Bejar

引用次数: 0

Consolidation chemotherapy in AML: Are we playing with a full deck of cards? AML的巩固化疗:我们是否在玩全套纸牌?

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2022-12-01 DOI: 10.1016/j.beha.2022.101408

Richard M. Stone

{"title":"Consolidation chemotherapy in AML: Are we playing with a full deck of cards?","authors":"Richard M. Stone","doi":"10.1016/j.beha.2022.101408","DOIUrl":"10.1016/j.beha.2022.101408","url":null,"abstract":"<div>The safe diminution of leukemic cell numbers to a level such that the patient will not succumb to their disease has been an achievable, yet often elusive goal in AML. Disease heterogeneity based both on biological features as well as on patient characteristics such as age, exposure to prior to anti-cancer chemotherapy and co-morbidities play a role in an allowing the physician to predict which patient has a greater or lesser chance to be cured after a diagnosis of acute myeloid leukemia. Cure rates range from 95% in younger patients with non-high-risk acute promyelocytic leukemia to essentially zero in older adults with intrinsically resistant biologies such as complex karyotype and/or TP53 mutations. One unifying feature of all AMLs, however, is the notion that whatever initial therapy is used, while possible to eradicate all morphological evidence of disease in a sizeable fraction of patients, an initial cycle (or two) is not sufficient to yield a low enough disease burden to prevent eventual relapse. Thus, the application of additional chemotherapy after the initial complete remission is received (post-remission therapy generally or consolidation therapy if a myelointense approach is used) is absolutely required for the patient to have a reasonable chance at cure. The widely accepted principle of the need to provide post-remission therapy leads to multiple controversies pertaining to the appropriate intensity, drug choice, and duration of exposure to consolidation chemotherapy, which can range from repetitive cycles of non-intensive therapy, up to and including a myeloblative allogeneic stem cell transplant. In this review, both the principles and the individual strategies that can be used once remission is achieved, will be examined.</div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"35 4","pages":"Article 101408"},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10473779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent progress in acute leukemia and myelodysplasia 急性白血病和骨髓异常增生的最新进展

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2022-12-01 DOI: 10.1016/j.beha.2022.101415

Hetty E. Carraway , Daniel A. Pollyea , Eytan M. Stein

引用次数: 0

How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms 我们如何改进MDS的疗效评估?改善MDS治疗模式疗效评估的策略

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2022-12-01 DOI: 10.1016/j.beha.2022.101405

Rafael Bejar

引用次数: 2

COVID-19 and antiphospholipid antibodies COVID-19和抗磷脂抗体

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2022-09-01 DOI: 10.1016/j.beha.2022.101402

Ayesha Butt , Doruk Erkan , Alfred Ian Lee

{"title":"COVID-19 and antiphospholipid antibodies","authors":"Ayesha Butt , Doruk Erkan , Alfred Ian Lee","doi":"10.1016/j.beha.2022.101402","DOIUrl":"10.1016/j.beha.2022.101402","url":null,"abstract":"<div>Antiphospholipid syndrome and the coagulopathy of COVID-19 share many pathophysiologic features, including endotheliopathy, hypercoagulability, and activation of platelets, complement pathways, and neutrophil extracellular traps, all acting in concert via a model of immunothrombosis. Antiphospholipid antibody production in COVID-19 is common, with 50% of COVID-19 patients being positive for lupus anticoagulant in some studies, and with non-Sapporo criteria antiphospholipid antibodies being prevalent as well. The biological significance of antiphospholipid antibodies in COVID-19 is uncertain, as such antibodies are usually transient, and studies examining clinical outcomes in COVID-19 patients with and without antiphospholipid antibodies have yielded conflicting results. In this review, we explore the biology of antiphospholipid antibodies in COVID-19 and other infections and discuss mechanisms of thrombogenesis in antiphospholipid syndrome and parallels with COVID-19 coagulopathy. In addition, we review the existing literature on safety of COVID-19 vaccination in patients with antiphospholipid antibodies and antiphospholipid syndrome.</div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"35 3","pages":"Article 101402"},"PeriodicalIF":2.1,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9549699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6